BigBear.ai appoints Sean Ricker as chief financial officer
Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc (NASDAQ:IONS), sold 6,849 shares of common stock on October 6, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week high of $71.87, with InvestingPro data showing an impressive 174% return over the past six months.
The shares were sold at a weighted average price of $69.02, with individual sales prices ranging from $69.02 to $69.03. The total value of the shares sold amounted to $472,717. Technical indicators from InvestingPro suggest the stock is currently in overbought territory, with the company’s market capitalization now reaching $11.2 billion.
Following the transaction, Swayze directly owns 30,453 shares of Ionis Pharmaceuticals Inc. He also indirectly owns 184 shares through his son.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2024.
In other recent news, Ionis Pharmaceuticals has seen significant developments. The company recently outlined its growth strategy, announcing plans for four product launches by 2026, with two already completed within the past nine months. Ionis Pharmaceuticals also anticipates four partner-led launches by the end of 2027. On the financial front, Stifel maintained a Hold rating on the company, raising its price target to $67, citing an updated assessment of the TTR market. Meanwhile, Oppenheimer increased its price target for Ionis to $90, maintaining an Outperform rating due to positive Phase 3 trial results for olezarsen and zilganersen. JPMorgan upgraded Ionis to Overweight, boosting its price target to $80 following successful trial data in severe hypertriglyceridemia and Alexander Disease. These updates were highlighted during Ionis’s recent Innovation Day, which showcased its pipeline progress and future plans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.